KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Acquisitions (2023 - 2025)

Historic Acquisitions for Regeneron Pharmaceuticals (REGN) over the last 3 years, with Q4 2025 value amounting to $300000.0.

  • Regeneron Pharmaceuticals' Acquisitions fell 9739.13% to $300000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $14.8 million, marking a year-over-year decrease of 7771.08%. This contributed to the annual value of $3.3 million for FY2025, which is 8000.0% down from last year.
  • As of Q4 2025, Regeneron Pharmaceuticals' Acquisitions stood at $300000.0, which was down 9739.13% from $3.0 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Acquisitions' 5-year high stood at $51.1 million during Q3 2023, with a 5-year trough of $300000.0 in Q4 2025.
  • Moreover, its 3-year median value for Acquisitions was $3.8 million (2023), whereas its average is $13.9 million.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Acquisitions soared by 20263.16% in 2024, and later tumbled by 9739.13% in 2025.
  • Over the past 3 years, Regeneron Pharmaceuticals' Acquisitions (Quarter) stood at $3.8 million in 2023, then soared by 202.63% to $11.5 million in 2024, then plummeted by 97.39% to $300000.0 in 2025.
  • Its last three reported values are $300000.0 in Q4 2025, $3.0 million for Q3 2025, and $11.5 million during Q4 2024.